Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
DRUG: Camrelizumab|DRUG: Apatinib|DRUG: S-1, Oxaliplatin
Pathological Complete Response (pCR), Defined as the percentage of subjects with no residual tumor cells in the primary tumor (Becker Grade 1a), Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment
Major pathological response (MPR), Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|total Pathologic complete response (tpCR), Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|R0 resection rate, Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|ypN staging, Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|Event free survival (EFS), Up to approximately 3 years|Disease-free survival (DFS), Up to approximately 3 years|Overall survival(OS), Up to approximately 5 years|AEs, Up to approximately 18 months
This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.